Humana (NYSE:HUM) Posts Earnings Results, Beats Expectations By $0.10 EPS

Humana (NYSE:HUM) issued its earnings results on Tuesday. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10, Zacks reports. Humana had a net margin of 1.18% and a return on equity of 13.20%. Humana updated its FY 2025 guidance to 16.250-16.250 EPS.

Humana Stock Down 2.7 %

Shares of Humana stock opened at $266.91 on Tuesday. Humana has a one year low of $213.31 and a one year high of $406.46. The company has a market cap of $32.14 billion, a P/E ratio of 23.64, a PEG ratio of 2.11 and a beta of 0.56. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The firm has a fifty day moving average of $274.21 and a two-hundred day moving average of $297.52.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Wells Fargo & Company decreased their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. TD Cowen raised their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Morgan Stanley increased their price target on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Barclays boosted their price objective on shares of Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 22nd. Finally, Truist Financial lifted their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Nineteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Humana has a consensus rating of “Hold” and an average target price of $297.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.